Recent Company News

• 05:00 PM ET Jul 08, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 04:49 AM ET May 12, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 04:16 PM ET Jul 07, 2025
  

  Nanobiotix announces regulatory harmonization and new composition of matter patent filed for JNJ-1900 (NBTXR3) (€4.16, 0.00)

• 04:16 PM ET May 21, 2025
  

  Nanobiotix provides Q1 2025 operational and financial update (€3.34, 0.00)

• 02:13 AM ET May 05, 2025
  

  Nanobiotix presents full results from the completed Phase 1 study evaluating JNJ-1900 (NBTXR3) in patients with locally advanced or borderline resectable pancreatic cancer (€3.05, 0.00)

• 04:23 PM ET Apr 02, 2025
  

  Nanobiotix reports FY net income (€68.1M) vs FactSet (€47.6M) [8 est, (€54.3)-(35.7M)] (€3.20, 0.00)

• 04:23 PM ET Mar 27, 2025
  

  Nanobiotix announces first data from the completed dose escalation part of a Phase 1 study evaluating NBTXR3 (JNJ-1900) as a 2L+ therapy for patients with locally advanced NSCLC (€3.37, 0.00)

• 04:19 PM ET Mar 20, 2025
  

  NANOBIOTIX announces presentation of data from two phase 1 studies evaluating JNJ-1900 (NBTXR3) at the European lung cancer conference (€3.46, 0.00)

• 09:17 AM ET Mar 18, 2025
  

  StreetAccount Summary - US Pre-market trading update